267 related articles for article (PubMed ID: 24935930)
1. Inhibition of PI3Kδ reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse.
Suárez-Fueyo A; Rojas JM; Cariaga AE; García E; Steiner BH; Barber DF; Puri KD; Carrera AC
J Immunol; 2014 Jul; 193(2):544-54. PubMed ID: 24935930
[TBL] [Abstract][Full Text] [Related]
2. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
[TBL] [Abstract][Full Text] [Related]
3. A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation.
Ji J; Fan H; Li F; Li X; Dong G; Gong W; Song Y; Liu F; Hua C; Tan R; Dou H; Hou Y
Immunol Lett; 2015 Dec; 168(2):355-65. PubMed ID: 26545567
[TBL] [Abstract][Full Text] [Related]
4. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus.
Barber DF; Bartolomé A; Hernandez C; Flores JM; Redondo C; Fernandez-Arias C; Camps M; Rückle T; Schwarz MK; Rodríguez S; Martinez-A C; Balomenos D; Rommel C; Carrera AC
Nat Med; 2005 Sep; 11(9):933-5. PubMed ID: 16127435
[TBL] [Abstract][Full Text] [Related]
5. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
Zhou L; Sun L; Wu H; Zhang L; Chen M; Liu J; Zhong R
Eur J Pharmacol; 2013 Sep; 715(1-3):230-7. PubMed ID: 23712004
[TBL] [Abstract][Full Text] [Related]
6. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
Steinmetz OM; Turner JE; Paust HJ; Lindner M; Peters A; Heiss K; Velden J; Hopfer H; Fehr S; Krieger T; Meyer-Schwesinger C; Meyer TN; Helmchen U; Mittrücker HW; Stahl RA; Panzer U
J Immunol; 2009 Oct; 183(7):4693-704. PubMed ID: 19734217
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of EZH2 Ameliorates Lupus-Like Disease in MRL/lpr Mice.
Rohraff DM; He Y; Farkash EA; Schonfeld M; Tsou PS; Sawalha AH
Arthritis Rheumatol; 2019 Oct; 71(10):1681-1690. PubMed ID: 31106974
[TBL] [Abstract][Full Text] [Related]
8. Enhanced phosphoinositide 3-kinase δ activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death.
Suárez-Fueyo A; Barber DF; Martínez-Ara J; Zea-Mendoza AC; Carrera AC
J Immunol; 2011 Sep; 187(5):2376-85. PubMed ID: 21810603
[TBL] [Abstract][Full Text] [Related]
9. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
10. Deficient leptin signaling ameliorates systemic lupus erythematosus lesions in MRL/Mp-Fas lpr mice.
Fujita Y; Fujii T; Mimori T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Tanaka M; Masaki Y; Fukushima T; Okazaki T; Umehara H
J Immunol; 2014 Feb; 192(3):979-84. PubMed ID: 24391210
[TBL] [Abstract][Full Text] [Related]
11. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.
Lu LD; Stump KL; Wallace NH; Dobrzanski P; Serdikoff C; Gingrich DE; Dugan BJ; Angeles TS; Albom MS; Mason JL; Ator MA; Dorsey BD; Ruggeri BA; Seavey MM
J Immunol; 2011 Oct; 187(7):3840-53. PubMed ID: 21880982
[TBL] [Abstract][Full Text] [Related]
12. Effect of nonmyeloablative unrelated fetal and neonatal murine peripheral blood mononuclear cell infusion on MRL/lpr mice.
Chuan W; Wu-qing W; Zhu-wen Y; Zuo L
Lupus; 2014 Sep; 23(10):994-1005. PubMed ID: 24756437
[TBL] [Abstract][Full Text] [Related]
13. (5R)-5-hydroxytriptolide ameliorates lupus nephritis in MRL/
Zhang LY; Li H; Wu YW; Cheng L; Yan YX; Yang XQ; Zhu FH; He SJ; Tang W; Zuo JP
Am J Physiol Renal Physiol; 2017 Apr; 312(4):F769-F777. PubMed ID: 28100505
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of transcription factor Blimp1 in systemic lupus erythematosus.
Luo J; Niu X; Liu H; Zhang M; Chen M; Deng S
Mol Immunol; 2013 Dec; 56(4):574-82. PubMed ID: 23911415
[TBL] [Abstract][Full Text] [Related]
15. CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus.
Chalmers SA; Wen J; Shum J; Doerner J; Herlitz L; Putterman C
Clin Immunol; 2017 Dec; 185():100-108. PubMed ID: 27570219
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
17. Involvement of infiltrating macrophage-derived activin A in the progression of renal damage in MRL-lpr mice.
Kadiombo AT; Maeshima A; Kayakabe K; Ikeuchi H; Sakairi T; Kaneko Y; Hiromura K; Nojima Y
Am J Physiol Renal Physiol; 2017 Feb; 312(2):F297-F304. PubMed ID: 27881396
[TBL] [Abstract][Full Text] [Related]
18. IK cytokine ameliorates the progression of lupus nephritis in MRL/lpr mice.
Muraoka M; Hasegawa H; Kohno M; Inoue A; Miyazaki T; Terada M; Nose M; Yasukawa M
Arthritis Rheum; 2006 Nov; 54(11):3591-600. PubMed ID: 17075801
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
Ma CC; Zhang CM; Tang LQ; Liu ZP
Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
[TBL] [Abstract][Full Text] [Related]
20. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
